Coegin Pharma (7Z6) Stock Overview
A biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
7Z6 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Coegin Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.31 |
| 52 Week High | SEK 0.58 |
| 52 Week Low | SEK 0.28 |
| Beta | 0.93 |
| 1 Month Change | 5.52% |
| 3 Month Change | -3.16% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -49.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7Z6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.3% | -1.6% | 1.5% |
| 1Y | n/a | -5.1% | 3.3% |
Return vs Industry: Insufficient data to determine how 7Z6 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7Z6 performed against the German Market.
Price Volatility
| 7Z6 volatility | |
|---|---|
| 7Z6 Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 7Z6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7Z6's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 3 | Jens Eriksson | coeginpharma.com |
Coegin Pharma AB, a biotechnology company, develops and commercializes cosmetic technologies for hair and skin in Sweden. Its flagship product is Follicopeptide, a patented, clinically developed peptide technology targeting hair thinning; and NPP-4, a cosmetic peptide product designed to enhance skin tone without UV exposure or chemicals. The company also develops FOL026, a peptide drug candidate for the treatment of myocardial infarction; AVX420, a drug candidate for the treatment of leukemia; and AVX001, a drug candidate for the topical treatment of both actinic keratosis and basal cell carcinoma.
Coegin Pharma AB Fundamentals Summary
| 7Z6 fundamental statistics | |
|---|---|
| Market cap | €9.49m |
| Earnings (TTM) | -€1.81m |
| Revenue (TTM) | €34.12k |
Is 7Z6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7Z6 income statement (TTM) | |
|---|---|
| Revenue | SEK 371.00k |
| Cost of Revenue | SEK 1.00m |
| Gross Profit | -SEK 630.00k |
| Other Expenses | SEK 19.07m |
| Earnings | -SEK 19.69m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | -169.81% |
| Net Profit Margin | -5,308.63% |
| Debt/Equity Ratio | 0% |
How did 7Z6 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 06:20 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coegin Pharma AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |